Analysis and Guide to Overseas Third-Generation IVF Technology and Suitable Candidates

Beginning: Real consultation experience

Ms. Lin, 35, walked into the consultation room with a thick stack of medical records. She had experienced two early miscarriages in natural pregnancies, and one chorionic villus karyotype analysis indicated trisomy 16. She asked: "I had third-generation IVF, so why did I still miscarry? Should I go abroad for third-generation IVF?" Behind this question lies a major misunderstanding among many patients regarding "overseas third-generation IVF" — equating "generation" with "success rate" and "overseas" with "more advanced." As a reproductive specialist, it is necessary to deconstruct from the underlying technical logic what this technology actually solves and what it does not.

What is overseas third-generation IVF

The medical term for third-generation IVF is Preimplantation Genetic Testing, abbreviated as PGT. It is based on conventional in vitro fertilization (IVF) and involves genetic analysis of embryos before transfer, selecting embryos with normal chromosome copy numbers or those not carrying specific pathogenic genes for transfer.

The core difference of overseas third-generation IVF lies in the fact that some countries or regions differ in the scope of applicable diseases for PGT, the embryo biopsy stage (day 3 cleavage stage or day 5 blastocyst trophectoderm cells), the testing platform (NGS vs. aCGH vs. SNP array), and legal regulations. These differences directly impact detection accuracy, the types of genetic diseases detectable, and the embryo availability rate.

When is it suitable

• Carriers of chromosomal structural abnormalities: Such as balanced translocation or Robertsonian translocation, the probability of a normal embryo in natural pregnancy is only 1/18 to 1/9.
• Families with a high incidence of single-gene genetic disorders: With a clear pathogenic gene locus, PGT-M can block inheritance.
• Advanced maternal age (≥38 years): The rate of embryonic aneuploidy increases exponentially with age; PGT-A can screen for euploid embryos.
• Recurrent implantation failure (≥2 transfers of good quality embryos without pregnancy): About 30-40% are related to embryonic chromosomal abnormalities.
• Recurrent miscarriage (≥2 miscarriages): Chromosomal abnormalities account for 50-70% of early miscarriage embryos.

When is it not suitable

• Infertility due to non-genetic factors: Such as tubal blockage, mild male factor, endometriosis. Conventional IVF/ICSI is sufficient; PGT does not increase live birth rate.
• Very low ovarian reserve (AMH < 0.5 ng/mL): Few eggs retrieved, insufficient number of blastocysts formed, may result in no embryo for transfer after PGT.
• Advanced age with excessive anxiety about embryonic mosaicism: PGT-A cannot completely rule out mosaicism, and some euploid embryos still carry a risk of miscarriage after transfer.
• Legal or ethical restrictions: Some countries do not allow PGT for sex selection or non-medical indications.

Why do these differences in indications exist

The core of PGT technology is to provide a screening tool for people at "high genetic risk," not to improve the overall IVF success rate. For patients with non-genetic factors, PGT cannot improve the intrinsic quality of embryos nor increase the cumulative live birth rate per single transfer. Overseas, different countries vary significantly in the scope of PGT-M testing — for example, the United States allows testing for HLA matching ("savior siblings"), while most European countries prohibit it.

Differences by age group

Age is a core variable affecting the benefit of PGT. The euploidy rate in women under 38 is about 50-60%, with limited marginal benefit from PGT-A; it drops to 30-40% for ages 38-40, where PGT-A can significantly reduce miscarriage rate; above 42, the euploidy rate is less than 20%, and although PGT-A can screen for transferable embryos, the overall live birth rate remains low. Reproductive specialists usually combine AMH, FSH, and antral follicle count to comprehensively assess the cost-effectiveness of PGT.

Differences by country

What is the specific process

1. Preparatory tests in home country (1-2 months): Includes karyotype analysis for both partners, carrier screening for thalassemia/spinal muscular atrophy, AMH, sex hormones, semen analysis, infectious disease screening (Hepatitis B, Syphilis, HIV, etc.).
2. Genetic counseling and protocol development: Reproductive specialist + genetic counselor jointly assess the feasibility of PGT-M/SR, confirming whether the pathogenic gene locus is detectable.
3. Visa and travel arrangements: Apply for a medical visa based on the chosen country, schedule the first appointment.
4. Overseas ovarian stimulation and egg retrieval (about 2 weeks): Start stimulation on day 2 of menstruation, egg retrieval after about 10-12 days, along with sperm collection.
5. Embryo culture and biopsy: Blastocysts form on day 5-6 after egg retrieval, biopsy of 3-5 trophectoderm cells, then embryos are frozen.
6. PGT testing (2-4 weeks): Biopsied cells are sent to a genetics lab for NGS or aCGH testing.
7. Frozen embryo transfer: After results are available, select a euploid embryo for frozen embryo transfer (usually in the next menstrual cycle after endometrial preparation).

What needs to be prepared

Documents and materials

• Valid passport (validity ≥ 6 months)
• Medical visa (some countries require a hospital invitation letter)
• Previous medical records, surgical records, original genetic reports and translations
• ID cards and marriage certificate for both parties (notarization required in some countries)

Medical preparation

• Female: AMH, FSH, LH, E2, antral follicle count, thyroid function, coagulation function
• Male: Semen analysis (including DFI), karyotype, Y chromosome microdeletion
• Both: Karyotype, carrier screening for thalassemia/spinal muscular atrophy, four infectious disease tests

How long does it take

From starting tests to completing the transfer, the overall cycle is about 3-6 months. Ovarian stimulation + egg retrieval takes about 2 weeks, embryo culture + PGT testing takes about 3-4 weeks, and the frozen embryo transfer cycle takes about 2-3 weeks. If probe customization for PGT-M is involved, an additional 6-8 weeks is required.

What are the risks

• Risk of no embryo for transfer (20-30%): Patients of advanced age or with low ovarian reserve produce few blastocysts, and all may be aneuploid after testing.
• Risk of undetected mosaicism: PGT-A cannot 100% detect low-level mosaicism; there is still a risk of miscarriage or abnormality after transfer.
• Testing failure or inconclusive results: DNA amplification failure from biopsied cells (about 1-3%), requiring re-biopsy or discarding the embryo.
• Overseas medical communication risks: Language barriers, incomplete medical records, difficulty handling legal disputes.
• Financial risk: Total cost of overseas PGT is about 150,000-300,000 RMB (including stimulation, egg retrieval, testing, transfer, medication, and travel). No refund if no embryo is available for transfer after testing.

How to determine if overseas third-generation IVF is suitable

Step 1: Confirm if there is a medical indication for PGT (chromosomal abnormality, single-gene disorder, advanced age, recurrent failure). Step 2: Assess whether similar PGT services are already available domestically — over 70 PGT institutions are approved in China, covering PGT-A/M/SR, at a much lower cost (about 50,000-80,000 RMB). Step 3: Only consider overseas if specific pathogenic genes cannot be tested domestically (e.g., rare mutations) or if the law does not permit it (e.g., HLA matching).

How to choose an overseas institution

• Laboratory accreditation: Whether it has CAP or CLIA certification, and whether the NGS platform is clinically validated.
• Genetic counseling system: Whether there is an independent genetic counselor responsible for report interpretation, rather than solely by the reproductive specialist.
• Embryo biopsy and testing timeline: Time from biopsy to report (usually 14-21 days), and the strategy for handling mosaic reports.
• Legal compliance: Whether PGT-M testing for your required condition is allowed, and whether sex selection is permitted (if needed).
• Patient data transparency: Whether stratified live birth rate data based on age, AMH, and number of biopsied embryos is provided, rather than a vague "success rate."

Easily overlooked details

• Importance of domestic karyotype report: Some overseas institutions do not require a domestic karyotype, but balanced translocation carriers who undergo PGT-A directly without PGT-SR may have missed detection.
• Combined assessment of AMH and FSH: Low AMH but normal FSH may still yield enough follicles; low AMH and FSH > 12 usually results in insufficient egg retrieval.
• Association between male sperm DFI and PGT: High DFI does not affect PGT testing but increases the risk of blastocyst formation failure.
• Endometrial preparation before transfer: After PGT testing, some patients may have their transfer cycle cancelled due to endometrial issues; advance planning is needed.

Common pitfalls

• Mistaken belief that "higher generation means higher success rate": Third-generation does not improve the success rate per single transfer but reduces miscarriage rate and the risk of passing on genetic diseases.
• Ignoring domestic PGT accessibility: Domestic PGT costs are only 1/3 to 1/2 of overseas prices, without the need for international travel.
• Being misled by "guaranteed success" packages: The probability of having no embryo for transfer after PGT objectively exists; any promise of a guaranteed success rate is unscientific.
• Overlooking the benefits and risks of transferring mosaic embryos: Some low-level mosaic embryos can develop into normal babies after transfer, but prenatal diagnosis is required for confirmation.

Frequently asked questions

Q1: Can I still undergo overseas third-generation IVF with low AMH?

When AMH ≥ 1.0 ng/mL, the expected number of eggs retrieved is ≥ 8, blastocysts formed ≥ 3, and the probability of having a transferable embryo after PGT is high. With AMH 0.5-1.0 ng/mL, it is still possible, but patients should be informed that there is about a 40% chance of no embryo for transfer. With AMH < 0.5 ng/mL, PGT is not recommended; consider egg donation or conventional IVF for egg accumulation first.

Q2: Can overseas third-generation IVF screen for all genetic diseases?

No. PGT-M can only detect specific mutations at known pathogenic gene loci. It cannot screen for de novo mutations, polygenic diseases (such as diabetes, hypertension), or mitochondrial genetic disorders (current technology is not yet mature).

Q3: Are embryos tested by PGT guaranteed to be healthy?

PGT can reduce the risk of chromosomal aneuploidy and specific single-gene disorders, but it cannot completely rule out mosaicism, methylation abnormalities, or rare structural abnormalities found during prenatal diagnosis.

Q4: Do I need to travel multiple times for overseas third-generation IVF?

Generally, two trips are needed: the first for ovarian stimulation and egg retrieval (about 2 weeks), and the second for frozen embryo transfer (about 1 week). Some institutions support remote protocol development and genetic counseling to reduce the number of trips.

Practitioner's observation

Over the past 8 years, I have encountered more than 400 patients who chose overseas PGT. The most common decision bias is "doing PGT for the sake of doing PGT," rather than based on medical indications. For patients under 35 with normal AMH and no genetic history, the improvement in cumulative delivery rate from PGT-A is minimal. The groups that truly benefit most from PGT are: carriers of balanced chromosomal translocations, carriers of single-gene disorders, and patients over 40 with recurrent implantation failure. The advantages of overseas PGT lie in the broader legal scope in some countries, a wider range of detectable diseases, and more flexible strategies for handling mosaic embryos. However, these advantages must be based on clear genetic counseling and informed decision-making.

Ending: Risk reminder